Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales

被引：0
|
作者：
Johns, A. [1 ]
Eatock, M. [2 ]
Johal, S. [3 ]
机构：
[1] Pfizer UK, Tadworth, England
[2] No Ireland Canc Ctr, Belfast, Antrim, North Ireland
[3] RTI Hlth Solut, Sheffield, S Yorkshire, England
来源：
NEUROENDOCRINOLOGY | 2012年 / 96卷
关键词：
sunitinib; overall survival; cost-utility; pancreatic net;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：38 / 38
页数：1
相关论文
共 47 条
  • [1] Cost-Effectiveness of Sunitinib in Patients (Pts) with Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the Netherlands
    Kansal, A.
    Chao, R.
    Patyna, S.
    Scheijbeler, H.
    Klok, R.
    Sandin, R.
    Sorensen, S.
    NEUROENDOCRINOLOGY, 2012, 96 : 39 - 39
  • [2] Cost-Effectiveness of Sunitinib in Patients with Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal
    Soares, M.
    Ines, M.
    Contente, M.
    NEUROENDOCRINOLOGY, 2012, 96 : 13 - 13
  • [3] Sunitinib (Su) in Progressive Pancreatic Neuroendocrine Tumor (PNET) Administered in Different Treatment Lines
    Marconcini, R.
    Bloise, F.
    Pusceddu, S.
    Femia, D.
    Bongiovanni, A.
    Stefano, R. F.
    Brizzi, M. P.
    Bruder, F.
    Spada, F.
    Antonuzzo, A.
    Falcone, A.
    Ricci, S.
    NEUROENDOCRINOLOGY, 2017, 105 : 220 - 220
  • [4] Sunitinib for advanced pancreatic neuroendocrine tumors
    Hubner, Richard A.
    Valle, Juan W.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (12) : 1817 - 1827
  • [5] Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors
    Bisht, Savita
    Feldmann, Georg
    Brossart, Peter
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (06) : 777 - 788
  • [6] Predictive Factors for Progression Free Survival (PFS) in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNET) Treated with Sunitinib
    Jimenez-Fonseca, P.
    Carmona, A.
    Solis, M.
    Faez, L.
    Ruiz, A.
    Rodriguez, D.
    Sanchez, M.
    Li, W.
    Menendez, M.
    Vieitez, J.
    Garrido, M.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 275 - 275
  • [7] Metastatic pancreatic neuroendocrine tumors (pNET): Placing current findings into perspective
    Phan, Alexandria T.
    CANCER TREATMENT REVIEWS, 2013, 39 (01) : 3 - 9
  • [8] FDA Approval Summary: Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
    Blumenthal, Gideon M.
    Cortazar, Patricia
    Zhang, Jenny J.
    Tang, Shenghui
    Sridhara, Rajeshwari
    Murgo, Anthony
    Justice, Robert
    Pazdur, Richard
    ONCOLOGIST, 2012, 17 (08) : 1108 - 1113
  • [9] The Efficacy of Everolimus and Sunitinib in Patients with Sporadic or Germline Mutated Metastatic Pancreatic Neuroendocrine Tumors
    Nunez, J. E.
    Donadio, M.
    Rocha Filho, D.
    Rego, J.
    Barros, M.
    Formiga, M. N.
    Lopez, R.
    Riechelmann, R.
    NEUROENDOCRINOLOGY, 2019, 108 : 176 - 176
  • [10] The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors
    Nunez, Jose Eduardo
    Donadio, Mauro
    Rocha Filho, Duilio
    Rego, Juliana Florinda
    Barros, Milton
    Formiga, Maria Nirvana
    Lopez, Rossana
    Riechelmann, Rachel
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 10 (04) : 645 - 651
12345